ClearPoint Neuro is progressing toward expedited FDA reviews for its therapies.
3 reports, 3 independent
Updated Aug 13
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ClearPoint Neuro is progressing toward expedited FDA reviews for its therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ClearPoint Neuro is moving toward expedited FDA reviews.1 source
ClearPoint Neuro received FDA authorization for the SmartFlow Neuro Cannula device and began commercial infusions.1 source
Keep exploring
The entities involved
-
ClearPoint Neuro (United States)
company in Irvine, United States
- FDA
Related events
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- The FDA is reviewing a drug approval application for a condition involving the company GAD.
- A clinical study led by Dr. Swee Lay Thein is underway at the National Institutes of Health and is subject to oversight by the Food and Drug Administration.
- A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
Coverage
Newest first; wire copies grouped- GuruFocus.comClearPoint Neuro Inc (CLPT) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... Total Revenue: $9.2 million for Q2 2025, up 17% from $7.9 million in Q2 2024. Biologics and Drug Delivery
- ZacksClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss o
- ACCESS NewswireClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint N